75P - Real-world data of adebrelimab in the first-line treatment of patients with small cell lung cancer

Background

Adebrelimab is a novel humanised IgG4 monoclonal antibody against PD-L1, indicated for the first-line treatment of adult Patients with ES-SCLC in China. A registry study was conducted with the use of disease-specific database of lung cancer, at 21 Centres in Jiangsu, China. Here, we report results of Cohort ADBL-LC-001: the efficacy and safety of adebrelimab in the first-line treatment of patients with SCLC.

Methods

We prospectively collected medical records from patients with SCLC, who initiated first-line treatment with adebrelimab. Primary endpoint is progression-free survival (PFS) by RECIST 1.1, secondary endpoints included overall survival (OS), objective response rate (ORR) , disease control rate (DCR) and safety.

Results

Between March 2023 and March 2024, 143 patients were included, the median follow-up was 10.3 months. Overall, 114(80%) patients were ES-SCLC and 29(80%) LS-SCLC, median age was 67 years (rang, 34-84), and most patients were ≥65 years (62%), male (78%), with an ECOG score of one (90%). 29 (25%) patients with ES-SCLC had liver metastases, 23 (20%) had Brain metastases. In the group ES-SCLC, mOS was 12.4 months (95% CI, 10.0-14.9) and mPFS was 6.7 months (95% CI, 5.3-7.7), the ORR, DCR was 34.2%, 85.1%, respectively. In the group LS-SCLC, mOS was 15.4 months (95% CI, 13.7-NA) and mPFS was 14.6 months (95% CI, 13.4-15.4), the ORR, DCR was 51.7%, 96.6%, respectively. In the IIT population, TEAEs occurred in 136 (95.1%) patients, grade 3 or worse TEAEs occurred in 29 (20.3%) patients. The most common grade ≥ 3 TEAEs were neutrophil count decreased (8.4%), lymphocyte count decreased (5.6%), anemia (3.5%), white blood cell decreased (2.8%), γ-glutamyltransferase increased (2.8%). The safety profile was generally manageable, without any unexpected adverse events. Table: 75P

The most common adverse events (incidence>20%)

Conclusions

This Real-world data verified the efficacy and safety of adebrelimab in the first-line treatment of patients with SCLC.

Legal entity responsible for the study

The authors.

Funding

Jiangsu Hengrui Pharmaceutical Co. LTD.

Disclosure

All authors have declared no conflicts of interest.